Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct;13(10):1225-31.
doi: 10.6004/jnccn.2015.0151.

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

Stuart A Grossman  1 , Susannah Ellsworth  1 , Jian Campian  1 , Aaron T Wild  1 , Joseph M Herman  1 , Dan Laheru  1 , Malcolm Brock  1 , Ani Balmanoukian  1 , Xiaobu Ye  1
Affiliations
Meta-Analysis

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

Stuart A Grossman et al. J Natl Compr Canc Netw. 2015 Oct.

Abstract

Background: The immune system plays an important role in cancer surveillance and therapy. Chemoradiation can cause severe treatment-related lymphopenia (TRL) (<500 cells/mm3) that is associated with reduced survival.

Materials and methods: Data from 4 independent solid tumor studies on serial lymphocyte counts, prognostic factors, treatment, and survival were collected and analyzed. The data set included 297 patients with newly diagnosed malignant glioma (N=96), resected pancreatic cancer (N=53), unresectable pancreatic cancer (N=101), and non-small cell lung cancer (N=47).

Results: Pretreatment lymphocyte counts were normal in 83% of the patient population, and no patient had severe baseline lymphopenia. Two months after initiating chemoradiation, 43% developed severe and persistent lymphopenia (P=.001). An increased risk for death was attributable to TRL in each cancer cohort (gliomas: hazard rate [HR], 1.8; 95% CI, 1.13-2.87; resected pancreas: HR, 2.2; 95% CI, 1.17-4.12; unresected pancreas: HR, 2.9; 95% CI, 1.53-5.42; and lung: HR, 1.7; 95% CI, 0.8-3.61) and in the entire study population regardless of pathologic findings (HR, 2.1; 95% CI, 1.54-2.78; P<.0001). Severe TRL was observed in more than 40% of patients 2 months after initiating chemoradiation, regardless of histology or chemotherapy regimen, and was independently associated with shorter survival from tumor progression.

Conclusions: Increased attention and research should be focused on the cause, prevention, and reversal of this unintended consequence of cancer treatment that seems to be related to survival in patients with solid tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in total lymphocyte count (TLC) over time in each individual disease cohort: (A) high-grade glioma; (B) resected pancreas cancer; (C) unresected pancreas cancer; and (D) non–small cell lung cancer.
Figure 2
Figure 2
Changes in lymphocyte count over time in the entire group of patients. Abbreviation: TLC, total lymphocyte count.
Figure 3
Figure 3
Relationship between survival and grade III/IV treatment-related lymphopenia in 297 patients with solid tumors. Pooled hazard ratio, 2.1; 95% CI, 1.54–2.78; P<.0001. Abbreviations: NSCLC, non–small cell lung cancer; TLC, total lymphocyte count.
Figure 4
Figure 4
Overall survival (stratified by total lymphocyte count) 2 months after initiating radiation therapy.
See this image and copyright information in PMC

References

    1. Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2011;6:824–833. - PubMed
    1. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103. - PMC - PubMed
    1. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–867. - PubMed
    1. Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110:1595–1605. - PMC - PubMed
    1. Oelkrug C, Ramage JM. Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol. 2014;178:1–8. - PMC - PubMed

Publication types

MeSH terms